4
Orphan Designations
0 approved, 4 designated
0
FDA Approvals
0
Active Trials
6
Rare Diseases
across 11 areas
0
News (30d)
Quiet
BPGbio, Inc is a company with 4 orphan drug designations across 6 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| coenzyme Q10 deficiency | coenzyme Q10 (CoQ10) | Des.TrialAppr. |
| coenzyme Q10 deficiency, primary, 1 | coenzyme Q10 (CoQ10) | Des.TrialAppr. |
| epidermolysis bullosa | ubidecarenone | Des.TrialAppr. |
| malignant glioma | Ubidecarenone | Des.TrialAppr. |
| malignant pancreatic neoplasm | ubidecarenone | Des.TrialAppr. |
| primary biliary cholangitis | coenzyme Q10 (CoQ10) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
21
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
21
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
0
affecting portfolio